Neoadjuvant therapy using PD-1 inhibitor plus chemotherapy with different intervals between chemotherapy cycles for locally advanced gastric or gastroesophageal junction cancer: A randomized phase 2 study.
Quanli Gao(Zhengzhou University), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Zibing Wang(Huazhong University of Science and Technology), Yang Gao(Chinese Academy of Agricultural Sciences), Yuzhou Zhao(Capital Medical University), Lingdi Zhao(Zhengzhou University), Chuang Shang(Zhengzhou University), Bin Zhang(Capital Medical University), Yongchao Xu(Henan Cancer Hospital), Weijie Zhao(Zhengzhou University), Zhiqiang Jiang, Jinxi Huang(Zhengzhou University), Peng Qin(Shenzhen Bay Laboratory), Zhimeng Li(Zhengzhou University), Xiangbin Wan(Zhengzhou University), Yingkun Ren(Zhengzhou University), Qiang Fu(Guangxi University), Chao-min Lu(Henan Cancer Hospital), Long Yuan(Zhengzhou University)
Cited by 0
Related Papers
Natural selection on <i>EPAS1</i> ( <i>HIF2α</i> ) associated with low hemoglobin concentration in Tibetan highlanders
|Proceedings of the National Academy of Sciences|2010|854
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
|Nature Immunology|2021|374
Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells
|Journal of Experimental & Clinical Cancer Research|2019|324
The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
|Cell Communication and Signaling|2020|232
Negative regulation of AMPK signaling by high glucose via E3 ubiquitin ligase MG53
|Molecular Cell|2021|176